Literature DB >> 17445493

Neurosarcoidosis.

Ashok V Patel1, David E Stickler, William R Tyor.   

Abstract

Neurosarcoidosis is an uncommon disorder and requires a careful clinical evaluation to reach a diagnosis. Generally, patients with peripheral symptoms, which include paresthesias, muscle weakness, and stocking glove deficits, have a better outcome compared with those with central nervous system involvement. Patients with mass lesions or hydrocephalus tend to have more relapses and are often more resistant to routine therapy. Neurosarcoidosis often responds to glucocorticoids, usually within days or weeks of initiating therapy. Patients are usually maintained on 40 to 80 mg per day for 4 to 6 weeks, which is then tapered slowly. Alternative treatments for refractory neurosarcoidosis, or to reduce or eliminate steroids, include methotrexate, cyclophosphamide, azathioprine, cyclosporine, infliximab, chlorambucil, chloroquine, and hydroxychloroquine.

Entities:  

Year:  2007        PMID: 17445493     DOI: 10.1007/bf02938405

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  39 in total

1.  Refractory neurosarcoidosis responding to infliximab.

Authors:  J A Pettersen; D W Zochodne; R B Bell; L Martin; M D Hill
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

2.  Refractory neurosarcoidosis: a dramatic response to infliximab.

Authors:  John D Carter; Joanne Valeriano; Frank B Vasey; Bryan Bognar
Journal:  Am J Med       Date:  2004-08-15       Impact factor: 4.965

3.  Determination of angiotensin-converting enzyme levels in cerebrospinal fluid is not a useful test for the diagnosis of neurosarcoidosis.

Authors:  J C Dale; J F O'Brien
Journal:  Mayo Clin Proc       Date:  1999-05       Impact factor: 7.616

4.  Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy.

Authors:  Sabrina Marangoni; Vincenza Argentiero; Bruno Tavolato
Journal:  J Neurol       Date:  2005-11-14       Impact factor: 4.849

5.  Epidemiology of familial sarcoidosis in the UK.

Authors:  D S McGrath; Z Daniil; P Foley; J L du Bois; P A Lympany; P Cullinan; R M du Bois
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

Review 6.  Extensive leptomeningeal and intraparenchymatous spinal cord neurosarcoidosis.

Authors:  A A Castellano-Sánchez
Journal:  South Med J       Date:  2000-08       Impact factor: 0.954

7.  Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.

Authors:  H L Weiner; G A Mackin; E J Orav; D A Hafler; D M Dawson; Y LaPierre; R Herndon; J R Lehrich; S L Hauser; A Turel
Journal:  Neurology       Date:  1993-05       Impact factor: 9.910

8.  Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen.

Authors:  John D Doty; Joseph E Mazur; Marc A Judson
Journal:  Chest       Date:  2003-11       Impact factor: 9.410

9.  Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement.

Authors:  O P Sharma
Journal:  Arch Neurol       Date:  1998-09

10.  Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations.

Authors:  B J Stern; D E Griffin; R A Luke; A Krumholz; C J Johns
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

View more
  6 in total

1.  Detection of clinical and subclinical retinal abnormalities in neurosarcoidosis with optical coherence tomography.

Authors:  Christopher Eckstein; Shiv Saidha; Elias S Sotirchos; Gita Byraiah; Michaela Seigo; Aleksandra Stankiewicz; Stephanie B Syc; E'tona Ford; Srilakshmi Sharma; Peter A Calabresi; Carlos A Pardo
Journal:  J Neurol       Date:  2012-01-04       Impact factor: 4.849

2.  UNUSUAL CLINICAL COURSE OF NEUROSARCOIDOSIS MANIFESTED WITH ACUTE HYDROCEPHALUS.

Authors:  Dragana Jovanović; Dana Grujičić; Mihailo Stjepanović; Spasoje Popević; Milica Kontić; Violeta Vučinić Mihailović
Journal:  Acta Clin Croat       Date:  2021-03       Impact factor: 0.932

Review 3.  The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Authors:  Aksel Siva; Sabahattin Saip
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

4.  A case with coincidental diagnosis of primary central nervous system lymphoma and lymph node sarcoidosis.

Authors:  Eva J Greiner; Lars-Olof Mügge; Bernd F M Romeike; Theodoros Topalidis; Bernhard Theis; Andreas Ragoschke-Schumm; Otto W Witte; Albrecht Günther
Journal:  J Neurooncol       Date:  2010-01-07       Impact factor: 4.130

Review 5.  Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.

Authors:  Domenico Plantone; Tatiana Koudriavtseva
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 3.580

6.  Hydrocephalus, a rare manifestation of sarcoidosis.

Authors:  Johan M van Rooijen; Gerritje S Mijnhout; Tom T A Aalders; R B J de Bondt
Journal:  Clin Pract       Date:  2011-09-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.